Kuzmich S, Vanderveer L A, Walsh E S, LaCreta F P, Tew K D
Department of Pharmacology, Fox Chase Cancer Center, Philadelphia, PA 19111.
Biochem J. 1992 Jan 1;281 ( Pt 1)(Pt 1):219-24. doi: 10.1042/bj2810219.
Subpopulations of HT 29 human colon carcinoma cells (HT/M and HT/S) were selected for resistance to the glutathione S-transferase (GST) inhibitor ethacrynic acid (EA). Both clones displayed a 2-fold resistance to the selection agent and required its constant presence for the maintenance of the resistant phenotype. Purification and characterization of GST isoforms showed similar profiles in the wild-type (WT) and EA-resistant clones, with microheterogeneous forms of the pi isoenzyme detected in each case. Metabolism of EA in vitro in the presence of GSH and the isolated GST from each cell line was characterized by a biphasic disappearance of the parent drug; the initial rate at which each of these enzymes metabolized EA was similar. These enzymes also displayed similar Km values for 1-chloro-2,4-dinitrobenzene. However, the amount of GST isolated per total cellular protein was 3.0-fold in HT/M and 1.6-fold in HT/S relative to WT in the continuous presence of EA. Under these conditions GST activity was increased by 2.3-fold in HT/M and 3.2-fold in HT/S as were GSH levels (2.7- and 4.1-fold for HT/M and HT/S respectively). When EA was removed, enzyme activity and GSH concentrations decreased to values similar to those of the WT. Slot-blot and Southern analyses of the DNA gave no evidence of GST-pi-gene amplification or rearrangement. However, RNA analyses by both slot-blot and Northern studies indicate a 2.5-3.5-fold elevation in the GST pi transcript in the EA-resistant population. Results from these studies indicate that: (1) maintenance of the EA-resistant phenotype requires constant presence of the agent; (2) the 2-fold resistance to EA can be quantitatively related to a 2-3-fold increase in GST activity and amount which appears to be the result of a 2.5-3.5-fold elevation in GST transcript; (3) EA, a Michael-reaction acceptor, can induce GST at the transcriptional level.
选用HT 29人结肠癌细胞亚群(HT/M和HT/S)使其对谷胱甘肽S-转移酶(GST)抑制剂依他尼酸(EA)产生抗性。两个克隆对选择剂均表现出2倍抗性,且需要其持续存在以维持抗性表型。GST同工型的纯化和特性分析显示,野生型(WT)和EA抗性克隆具有相似的图谱,每种情况下均检测到pi同工酶的微不均一形式。在谷胱甘肽(GSH)存在下,EA在体外的代谢以及从每个细胞系分离得到的GST的特征是母体药物呈双相消失;这些酶各自代谢EA的初始速率相似。这些酶对1-氯-2,4-二硝基苯也表现出相似的米氏常数(Km)值。然而,在持续存在EA的情况下,相对于WT,HT/M中每总细胞蛋白分离得到的GST量为3.0倍,HT/S中为1.6倍。在这些条件下,HT/M中GST活性增加了2.3倍,HT/S中增加了3.2倍,GSH水平也分别增加了2.7倍和4.1倍。当去除EA时,酶活性和GSH浓度降至与WT相似的值。DNA的狭缝印迹和Southern分析未发现GST-pi基因扩增或重排的证据。然而,通过狭缝印迹和Northern研究进行的RNA分析表明,EA抗性群体中GST pi转录本升高了2.5 - 3.5倍。这些研究结果表明:(1)维持EA抗性表型需要该药剂持续存在;(2)对EA的2倍抗性在数量上可能与GST活性和量增加2 - 3倍有关,这似乎是GST转录本升高2.5 - 3.5倍的结果;(3)EA作为迈克尔反应受体,可在转录水平诱导GST。